TowardPi closes second funding round this year with E+ investment
TowardPi
High-end Ophthalmic Medical Device Developer
Recently, TowardPi (Beijing) Medical Technology Ltd. ("TowardPi") announced the close of its E+ funding round. The investment was led by the fund under Beijing State-owned Capital Operation and Management Company Limited, with continued participation from key existing shareholder Tsinghua Innovation Ventures. This marks the company's second successful funding round this year, following its Series E closed earlier, and is set to bolster confidence in China's high-end ophthalmic equipment sector.
TowardPi achieves five major milestones within one year:
March 2025: Completed a Series E financing round amounting to approximately 500 million yuan, representing the largest single fundraising round in China's primary market for ophthalmic equipment.
March 2025: Yin Li, Member of the Political Bureau of the CPC Central Committee and Secretary of the Beijing Municipal Committee, conducted a research visit to TowardPi Medical.
May 2025: TowardPi's OCT technology was awarded the Second Prize of the Beijing Science and Technology Progress Award.
August 2025: Premier Li Qiang investigated the development of Beijing's biopharmaceutical industry, during which TowardPi Medical delivered a comprehensive report on its work.
September 2025: Beijing State-owned Capital Operation and Management Company and Tsinghua Innovation Ventures completed a new round of investment in the company.
TowardPi, leveraging its robust in-house core component R&D capabilities and strong market reputation, joined ZEISS as the only two companies in the Chinese market to have all four of their major product lines (surgical microscopes, OCT, ultra-widefield cameras, and biometers) rank within the top five in market share during the first three quarters of 2025, according to statistics from disclosed ophthalmic equipment bidding data.
Based on the bidding data for the first three quarters of 2025, TowardPi's ophthalmic OCT products maintained their top position in both total winning bid value and total unit volume. Their market share by value reached 38.7%, further extending their leading advantage. In global expansion, since obtaining CE certification in 2024, TowardPi has rapidly sold over 100 OCT units overseas. During the same period, its market share entered the top five in Europe, while achieving the highest average selling price in the European market.
Beyond OCT, the company's ophthalmic surgical microscopes, as its second growth curve, ranked fourth in total winning bid value in the first three quarters (with the top three positions all held by imported brands), while achieving the highest industry average selling price (ASP) of RMB 4.529 million. Furthermore, the company's ultra-widefield fundus cameras and biometers also achieved strong market positions, ranking fourth and third in total winning bid value, respectively. This successfully fulfills their strategic role in completing the company's comprehensive product portfolio.
The development of other key products, including a phaco-vitrectomy system, neurosurgical microscopes, and a femtosecond laser cataract surgical system, is progressing steadily. These products are expected to be launched sequentially over the next 2-3 years.